CymaBay Therapeutics, Inc.
Symbol: CBAY
NASDAQ
32.48
USDTržní cena dnes
-32.9591
Poměr P/E
0.0000
Poměr PEG
3.73B
MRK Cap
- 0.00%
Výnos DIV
CymaBay Therapeutics, Inc. (CBAY) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1283.24 | 394.3 | 135.5 | 186.5 | ||||||||||||
balance-sheet.row.short-term-investments | 708.35 | 187.7 | 115.2 | 60.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 35.01 | 9.5 | 2.6 | 4.6 | ||||||||||||
balance-sheet.row.total-current-assets | 1318.25 | 403.8 | 138.1 | 191.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.83 | 5.7 | 0.9 | 1.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 22.36 | 22.4 | 0 | 8.1 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 9.26 | 2.8 | 2.9 | 1.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 39.45 | 30.9 | 3.8 | 11.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.account-payables | 12.78 | 3.8 | 1.1 | 2.7 | ||||||||||||
balance-sheet.row.short-term-debt | 11.12 | 10 | 0.7 | 0.6 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 397.14 | 99.2 | 90.3 | 51 | ||||||||||||
Deferred Revenue Non Current | 3.3 | 1.1 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -203.34 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 58.31 | 21.3 | 13.7 | 15.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 405.76 | 105.6 | 90.3 | 51 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 6.43 | 5.3 | 0.7 | 1.3 | ||||||||||||
balance-sheet.row.total-liab | 526.66 | 142.4 | 105.7 | 69.4 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.06 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3718.63 | -978.2 | -872.9 | -766.9 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.11 | 0.1 | -0.3 | 0 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4549.72 | 1270.3 | 909.3 | 899.8 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1357.7 | - | - | - | ||||||||||||
Total Investments | 730.71 | 210.1 | 115.2 | 68.8 | ||||||||||||
balance-sheet.row.total-debt | 413.58 | 114.5 | 90.9 | 51.6 | ||||||||||||
balance-sheet.row.net-debt | -161.31 | -92 | 70.6 | -74.2 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -105.37 | -105.4 | -106 | -90 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.77 | -2.7 | 0 | 0.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 15.23 | 15.2 | 9.5 | 10 | ||||||||||||
cash-flows.row.change-in-working-capital | 5.63 | 5.6 | -2.3 | 6.4 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | 2.73 | 2.7 | -1.4 | 2.3 | ||||||||||||
cash-flows.row.other-working-capital | 2.9 | 2.9 | -0.9 | 4 | ||||||||||||
cash-flows.row.other-non-cash-items | 19.06 | 14 | 14 | 2.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -72.53 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.acquisitions-net | -2.11 | -7.9 | -0.9 | 0.6 | ||||||||||||
cash-flows.row.purchases-of-investments | -305.67 | -305.7 | -175 | -78.1 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 219.55 | 219.6 | 129.1 | 126.8 | ||||||||||||
cash-flows.row.other-investing-activites | 2.11 | 7.9 | 0.9 | -0.6 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -86.57 | -86.6 | -46 | 48.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -25 | -47.7 | ||||||||||||
cash-flows.row.common-stock-issued | 339.36 | 345.8 | -0.5 | 70.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -0.5 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -25 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 7.46 | 335.1 | 75.5 | 95.7 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 345.77 | 345.8 | 24.6 | 118.5 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 26.59 | -0.4 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 186.24 | 186.2 | -105.5 | 97.6 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 574.89 | 206.5 | 20.3 | 125.8 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 388.64 | 20.3 | 125.8 | 28.2 | ||||||||||||
cash-flows.row.operating-cash-flow | -72.53 | -72.5 | -84.1 | -69.4 | ||||||||||||
cash-flows.row.capital-expenditure | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.free-cash-flow | -72.98 | -73 | -84.2 | -69.5 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 31.07 | 31.1 | 0 | 0 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
income-statement-row.row.gross-profit | 30.39 | 30.4 | -0.7 | -0.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 80.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 51.95 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 132.7 | 132.1 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 132.75 | 132.8 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.interest-income | 13.49 | 13.5 | 2 | 0.2 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 3.18 | 0.7 | 2 | 0.9 | ||||||||||||
income-statement-row.row.ebitda-caps | -94.8 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -101.68 | -101.7 | -93.1 | -87.6 | ||||||||||||
income-statement-row.row.income-before-tax | -105.37 | -105.4 | -106 | -90 | ||||||||||||
income-statement-row.row.income-tax-expense | 11.99 | 0 | 12.9 | 2.6 | ||||||||||||
income-statement-row.row.net-income | -111.68 | -105.4 | -118.9 | -92.6 |
Často kladené otázky
Co je CymaBay Therapeutics, Inc. (CBAY) celková aktiva?
CymaBay Therapeutics, Inc. (CBAY) celková aktiva jsou 434686000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 57000.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.978.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.644.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je -3.594.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -3.272.
Co je CymaBay Therapeutics, Inc. (CBAY) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -105370000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 114494000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 132071000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 206535000.000.